University of North Dakota

UND Scholarly Commons
Physical Therapy Scholarly Projects

Department of Physical Therapy

2014

Sarcopenia and Current Research Using Ames
Dwarf Mice: A Research Study
Amanda Sodemann
University of North Dakota

Follow this and additional works at: https://commons.und.edu/pt-grad
Part of the Physical Therapy Commons
Recommended Citation
Sodemann, Amanda, "Sarcopenia and Current Research Using Ames Dwarf Mice: A Research Study" (2014). Physical Therapy
Scholarly Projects. 637.
https://commons.und.edu/pt-grad/637

This Scholarly Project is brought to you for free and open access by the Department of Physical Therapy at UND Scholarly Commons. It has been
accepted for inclusion in Physical Therapy Scholarly Projects by an authorized administrator of UND Scholarly Commons. For more information,
please contact zeineb.yousif@library.und.edu.

SARCOPENIA AND CURRENT RESEARCH USING AMES DWARF MICE:
A RESEARCH STUDY

by

Amanda Sodemann
Bachelor of Science, Concordia University Wisconsin, 2011

A Scholarly Project Submitted to the Graduate Faculty of the

Department of Physical Therapy
School of Medicine

University of North Dakota

In partial fulfillment of the requirements for the degree of

Doctor of Physical Therapy

Grand Forks, North Dakota
May, 2014

This Scholarly Project, submitted by Amanda Sodemann in partial fulfillment of the
requirements for the Degree of Doctor of Physical Therapy from the University of North
Dakota, has been read by the Advisor and Chairperson of Physical Therapy under whom
the work has been done and is hereby approved.

_________________________________
(Graduate School Advisor)
_________________________________
(Chairperson, Physical Therapy)

ii

PERMISSION
Title
Study

Sarcopenia and Current Research Using Ames Dwarf Mice: A Research

Department Physical Therapy

Degree

Doctor of Physical Therapy

In presenting this Scholarly Project in partial fulfillment of the requirements for a
graduate degree from the University of North Dakota, I agree that the Department of
Physical Therapy shall make it freely available for inspection. I further agree that
permission for extensive copying for scholarly purposes may be granted by the professor
who supervised my work or, in his absence, by the Chairperson of the department. It is
understood that any copying or publication or other use of this Scholarly Project or part
thereof for financial gain shall not be allowed without my written permission. It is also
understood that due recognition shall be given to me and the University of North Dakota
in any scholarly use which may be made of any material in this Scholarly Project.

Signature ____________________________

Date

iii

____________________________

TABLE OF CONTENTS
LIST OF TABLES………………………………………………………….…………….v
ABSTRACT…………………………………………………………….……………….vi
CHAPTER
I.

INTRODUCTION AND LITERATURE ……………….……………….1

II.

RESEARCH DESCRIPTION……………………………….…………...3
What is sarcopenia and how it is classified?.....................................4
The role of Ames dwarf ….…………………….……………….11

III.

METHODS……………………………………….…………………….14
Skeletal Muscle Tissue Acquisition.....………………………….14
Slicing Muscle Tissue.…………………………………………..15
Hematoxylin And Eosin Staining.………………………………16
Immunohistochemistry For Mouse Myosin Heavy Chains.…….16
Muscle Fiber Counting………………………………………….18
Determining Cross-Sectional Muscle Area……………………..18

IV.

RESULTS………………………………………………………………20

V.

DISCUSSION…………………………………………………………..25

REFERENCES…………………………………………………………………………27

iv

LIST OF TABLES
Table 1: Muscle fiber counts for SOL in wild type mice. Fast vs. slow twitch………….20
Table 2: Muscle fiber counts for SOL in Ames dwarf mice. Fast vs. slow twitch………21
Table 3: Cross-sectional areas for 12 month old, wild type mouse N4. …...……………22
Table 4: Cross sectional area for 3 month old, wild-type mouse N2. …..………………22
Table 5: Cross sectional area for 6 month old, dwarf mouse, D1. ……………………...23

v

ABSTRACT
This research project focused on the differences observed in muscle fiber
composition and surface area between wild type mice and Ames dwarf mice as they aged.
A mouse model was utilized because the skeletal muscle framework of mice closely
resembles that of human muscle; thus, the observations seen within the mice may also be
seen within humans as they age. Comparisons between the wild type and dwarf mice
include a smaller cross-sectional muscle area in a dwarf mouse and no drastic change in
the percentages of fast and slow twitch muscle fibers as the dwarf mouse ages.
Furthermore, differences in fiber length and cross-sectional muscle area between wild
type and dwarf mice were revealed. However, exact conclusions on muscle fiber
composition and surface area as mice age cannot be drawn secondary to the limited
number of lower extremity musculature that was obtained. Current knowledge of
sarcopenia and its effects were also explored throughout this paper.
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CHAPTER I
INTRODUCTION AND LITERATURE REVIEW
Sarcopenia has become increasingly prevalent in the population secondary to
increased longevity of life seen in communities. It is expected that sarcopenia will
continue to steadily escalate in the population as the anticipated life expectancy rises;
furthermore, the population of adults aged 65 and over will double within the next 15
years.1 With these projected outcomes, age-related losses in skeletal muscle mass and
function will become a crucial aspect in the provided health services. These functional
declines can contribute to the increased hospitalizations secondary to falls and subsequent
hip fractures; hence, there may be an increased prevalence of gait disorders and balance
disturbances in the elderly. Currently, the term sarcopenia is being used interchangeably
with loss of muscle mass, strength, and function. Loss of muscle mass and strength,
cognitive decline, and a decrease in overall physical functioning are associated with the
aging process. The loss of muscle mass and strength can occur as early as the third
decade of life but is most commonly seen in the fourth decade and beyond.2,3 However,
there is conflicting evidence surrounding the age at which cognitive decline begins. Some
researchers argue cognitive decline starts in the sixth decade of life; whereas, others have
suggested it can appear as early as the second or third decade.4
Research has proposed decreased participation in physical activity leads to the
gradual loss of muscle mass (atrophy); however, several other factors may also contribute
1

to loss of strength and muscular atrophy. Clinically relevant questions center on how to
define sarcopenia. Once sarcopenia is defined, how does one medically treat it and are
there therapeutic rehabilitative approaches? Are there ways to prevent sarcopenia? The
following paragraphs will aim to answer these questions. Furthermore, the meaningful
role that Ames dwarf mice play in sarcopenia research will be discussed.
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CHAPTER II
RESEARCH DESCRIPTION
Research’s efforts have revealed that by the time a person reaches the age of 50,
there is an average decline of 1% to 2% of muscle mass per year. By age 80, a person’s
muscle mass decline has reached approximately 50%. Once muscle mass falls below two
standard deviations of the mean of a standardized young control group and gait speed
declines to 0.8 m/s2, a clinical diagnosis of sarcopenia is concluded. It is estimated that
5% to 13% of persons aged 60 to 70 years are affected by this disorder; this percentage
increases to 11% to 50% for persons aged 80 years and older.5 Another group of
researchers conclude that females aged 75 years and older lose approximately 0.64% to
0.7% in muscle mass per year; whereas, males aged 75 years and older tend to lose 0.8%
to 0.98% per year. Furthermore, the loss of muscular strength is considered to be 2 to 5
times greater than the loss of muscle mass.3 Advanced skeletal muscle loss may affect a
person’s quality of life, the need for support services, and eventually long term care.6
This loss of muscular strength is a consistent risk factor for the development of
disabilities associated with sarcopenia.3 Ultimately, the ability to climb stairs, ambulate,
maintain proper balance and posture, and transfer from sit to stand will become
increasingly strenuous and difficult.
Experimental research using molecular genetics has revealed several
pathophysiological disturbances that occur with sarcopenia. Molecular genetics seeks to
3

identify alterations in protein arrangements and the effects these alterations have on the
organism. In the molecular genetics research of sarcopenia, there have been several
discoveries which have aided in establishing further research projects and a more broadbase of knowledge in muscle tissue proteomics. These discoveries include the
association of age-dependent muscular wasting with impaired muscle protein synthesis,
impaired metabolic pathways, disrupted ion homeostasis, unbalanced levels of growth
factors and hormones, excitation and muscular contraction uncoupling, reduced cellular
stress response, heightened susceptibility to apoptosis, and diminished regenerative
capacity.7 Through the use of molecular genetics and proteomics, sarcopenia is now more
accurately defined.
What is sarcopenia and how it is classified?
Researchers have created several possible definitions for sarcopenia. One
definition states that decreased muscle strength, (which was represented by knee
extension isometric torque in this study), handgrip strength, lower extremity muscle
power, and physical performance measured by gait speed are indicative of sarcopenia.
Another definition states muscle strength or function has a direct correlation with muscle
mass; therefore, if muscle mass decreases, it can be assumed that the strength of the
muscle would also diminish. For example, one with low muscle mass would most likely
have a decreased gait speed secondary to the reduced amount of muscular power
produced by muscles. Muscular power is lost before muscular strength. Muscle power is
defined as the ability to generate as much force as quickly as possible; whereas, strength
is defined as the ability to generate as much force as possible under no time constraints.
Mathematically, power is calculated by dividing work by time; strength is calculated by
4

multiplying the mass and distance it has traveled (or work it has done). While both
muscle power and strength are important for functional daily activities, power is better at
predicting the ease in which functional activities are performed; thus, a person who has
decreased gait speed more than likely has a decreased ability to generate adequate muscle
power to efficiently contract his lower extremity muscles to move in a forward
progression.2,8
However, different researchers have argued the term sarcopenia describes
alterations in muscle structure, function, and body composition which lead to weakness
and dysfunction. At the time, the term was mainly used as a major determinant in the
decline of physical function and seen as a risk factor for disability and disease. Other
early definitions include any type of muscle loss due to disease, any person who required
the use of an assistive device, and any person who has had a history of falls.9
In 1998, researchers began developing methods of classification and diagnostic
criteria for sarcopenia; these are still utilized in determining the severity of the disease.
Sarcopenia classification began with using mathematical formulas. Different
mathematical formulas have been suggested to define the rate of sarcopenia. One formula
demonstrates sarcopenia as appendicular skeletal mass (ASM), which is the sum of lean
mass for both arms and legs, divided by the height squared (kg/m2).2,10 Values that were
at least two standard deviations below the mean of a reference population were classified
as having sarcopenia. Another formula that was introduced used muscle mass; this
formula corrected muscle mass for a combination of height, fat mass, or total body mass.2
Formulas used to compute this percentage included ASM (kg) = 0.2487 (weight) +
5

0.0483(height) -0.1584(hip circumference) + 0.0732(grip strength) +2.5843(sex) +
5.8828 for determination of muscle mass and percentage of body fat = 0.2034(waist
circumference) + 0.2288(hip circumference) + 3.6827(In triceps skinfold)- 10.9814(sex) 14.3341.10 The latter formula was derived using the bioelectrical impedance analysis
(BIA) equation which was cross-validated with magnetic resonance imaging (MRI)
measures of whole body muscle mass and body mass index. This particular study found a
correlation of 0.93 and a 9.0% standard error of the estimate between MRI and the BIA
equation. From this study, absolute muscle mass in kilograms (kg), was normalized for
height and termed skeletal muscle index (SMI).11 These formulas have been utilized to
generate criteria to diagnose sarcopenia.
Diagnostic criteria correlate to the understanding of related consequences low
muscle mass has on a person’s ability to execute daily and vocational functions. Evidence
has shown muscle mass is associated with a person’s self-reported physical disability and
functional impairments.2 It has been recently suggested the main criteria for sarcopenia
diagnosis include low muscle mass greater than two standard deviations below the mean,
low muscle strength, diminished physical performance, and gait speed less than 0.8m/s2.5
Contributing factors to this diagnosis are chronic inflammation, reduced protein intake,
motor neuron atrophy, and immobility.12
Physicians are now classifying sarcopenia by severity using SMI. In order to
determine “normal” skeletal muscle mass, SMI values were obtained from young persons
aged 18 to 39 years old. Classification criteria for sarcopenia were derived using the SMI
values from the young population.6 Class I sarcopenia is defined as SMI that is between
6

one and two standard deviations below the young adult values; it is most commonly
associated with increased difficulty in stooping, crouching, kneeling, and ability to
perform tandem stance. Class II sarcopenia is SMI that is greater than two standard
deviations below the young adult values; it is most commonly associated with increased
difficulty in climbing 10 stairs, lifting/carrying 10 pounds, rising to a stand from a chair,
and decreased ability to perform household chores. A normal SMI is considered to be
within one standard deviation of the gender-specific mean for young adults. The
researchers utilized this approach because it was considered comparable to the use of
bone mineral density of a young reference group for classifying normal bone density,
osteopenia, and osteoporosis. It was discovered the prevalence of class I and class II
sarcopenia increased from the third to sixth decades, but remained relatively constant in
the seventh decade and beyond.6,9 Sarcopenia classification can be further aided by a
physician’s prescription for diagnostic imaging.
Imaging is also routinely performed in the diagnosis of sarcopenia; the most
common imaging techniques include MRI, dual energy X-ray absorptiometry (DEXA),
and bioelectrical impedance analysis (BIA). MRIs allow the radiologist to determine
segmental and total muscle mass, and assess overall muscle quality through calculating
fat infiltration in muscle. DEXA has the advantage of analyzing body composition and is
currently used as the procedure of choice for bone mineral density. BIA is currently
recognized as the most specific exam to assess lean muscle mass and body fat. It is a
routine exam that assesses body composition by focusing in on the molecular level, as a
representation of the amount of muscle mass.12 It measures tissue resistance through an
electrical signal to determine the proportion of body fat to lean mass. This calculation is
7

done as the signal’s current easily flows through parts of the body that are composed
mainly of water such as blood, urine, and muscle.13 This technique is a reliable analysis
in the study for lean mass versus muscle mass. BIA has several advantages including no
radiation exposure, relatively inexpensive, requires no specialized staff, and is a portable
machine; hence, the test can be completed at the patient’s bedside.12 In a study done by
Janssen and colleagues, they revealed that the BIA has greater precision in classifying
class II sarcopenia and estimating the percentage of skeletal muscle mass than the other
aforementioned methods.6 Sarcopenia classification is accomplished through utilizing
SMI young adult values attained through previous research. Type I sarcopenia is defined
as SMI that is between one and two standard deviations below the young adult values and
type II is classified as being greater than two standard deviations compared to young
adult values.6 In another study, researchers concluded BIA using vector analysis was
sensitive in determining body mass differences; however, it was not as sensitive in the
assessing specific features of a person’s body composition. Furthermore, they discovered
BIA could also be used in determining nutritional status in the elderly secondary to the
ability to recognize individuals with different quantities of absolute mass. They
concluded this newer technique of utilizing vector analysis may be applicable in finding
several age-related conditions including sarcopenia and sarcopenic obesity.14
Now that there is an understanding of how sarcopenia is classified and diagnosed,
it is important to recognize how the muscle fiber and motor unit is structured, how much
energy/power is required for muscle contraction, and how functional impairments occur
as the muscle motor unit ages. Power for a muscular contraction occurs within the actin
and myosin components of the sarcomere. Myosin plays an important role as it aids in the
8

differentiation of motor unit subtypes. Three motor unit types exist: slow oxidative, fastfatigable, and fast fatigue-resistant motor units. In general, slow oxidative motor units
have the smallest number of muscle fibers and are principally composed of type I myosin.
These motor units will contract with slow velocity and are usually recruited for fine
motor activities and gravity opposition. Unique characteristics of fast-fatigable motor
units are high numbers of muscular fibers and the large cross-sectional areas.
Additionally, they have the highest contractile velocity and are composed mainly of type
IIb fibers, (now known as IIx in humans), and myosin, which transfer energy at a much
higher rate than slow motor units. Any activity that requires a maximal power
generation, such as weight-lifting or sprinting, will recruit fast-fatigable motor units. Fast
fatigue-resistant motor units are composed of type I, type IIa, and type IIb muscle fibers.
Transfer of energy occurs at a slower rate than fast-fatigable motor units, but faster than
slow oxidative motor units.1
Several aging processes can result in alterations in mass, composition, contractile
properties, and mechanical properties of skeletal muscle tissue. One such process is the
loss of slow and fast motor units and atrophy of muscle fibers as described above.
Denervation of motor units result in this loss; in order to compensate, the remaining
motor units will convert the denervated fiber type to that of the motor unit. Consequently,
type II fast-fatigable fibers are converted into slow type I fibers.1 This transition of fastto- slow muscle fibers is apparent with physical exercise, low-frequency stimulation,
hyper-excitability, and aging; these effects are most commonly seen in sarcopenic muscle.
Researchers have suggested these muscle fiber transitions are most likely caused by a
secondary occurrence. They are a result of faulty reinnervation mechanisms post
9

denervation, apoptosis-triggered loss of spinal motor neurons, and selective atrophy of
type II fibers.
In contrast, slow-to-fast muscle fiber transitions (type I to type II) are commonly
associated with disuse atrophy, extensive bed rest, and microgravity.7 Muscular atrophy
is characterized by a reduction in muscle fiber cross-sectional area, sarcomere dissolution,
decreased mitochondria, and greater amounts of connective tissue within the muscle.
Type I muscle fibers are the first to atrophy; type II fibers will start to atrophy later.
Researchers suggest this finding is secondary to the extensive use of type I fibers; the
majority of muscular contractions recruit type I fibers before type II fibers. Hence, it
would be logical that with muscular atrophy, type I fibers lose their primary
characteristics and begin to imitate the characteristics of type II fibers.15 The loss of both
type I and type II fibers accelerates age-related alterations in muscle function. This
progression of muscle function degenerative modification develops as muscle fibers
undergo a shift from anaerobic-oxidative metabolism to aerobic-oxidative metabolism.
Aerobic-oxidative metabolism shifts have been researched through proteomics,
the study of protein structures and functions. Emerging scientific research aims to
observe ongoing intercellular transformations as the proteome is subjected to variable
environments. Thus far, proteomic profiling has established extensive adjustments made
in the expression patterns of specific proteins in aging skeletal muscle. These adjustments
include enzymatic metabolic pathways, elements of the cellular stress response, and ion
homeostasis regulatory components. One finding discovered that pyruvate kinase, a ratelimiting glycolytic enzyme, is significantly reduced in aged skeletal muscle; however,
10

essential mitochondrial proteins are amplified in sarcopenia. This discovery proposed a
shift from anaerobic-oxidative to aerobic-oxidative metabolism, hence, altering the way
in which muscle fibers respond to physical stressors.
The role of Ames dwarf mice
Numerous studies have been conducted on the protein arrangement of muscle
fibers as they age. Comparisons between human skeletal muscle and mouse skeletal
muscle are most common because the skeletal muscle in mice closely resembles that of
human skeletal muscle. Since mice are frequently used for experimental research, these
experiments are easily performed and provide a wealth of knowledge surrounding this
particular diagnosis.16
Several mouse models, Ames dwarf mice included, carry specific genetic
mutations which are associated with increased life span. Additionally, they have
diminished levels of mitochondria and endogenous reactive oxygen species (ROS), and
an increased resistance to oxidative stress. These mutations are beneficial in mediating
longevity, thus extending their lifespan. Researchers have hypothesized that ROSmediated oxidative damage is an essential component in determining longevity. They
suggest that these physiological characteristics of mitochondrial function are developed
early in life and continue throughout the life cycle. Moreover, Ames dwarf mice also
have unique hormonal characteristics; they lack growth hormone (GH), thyroid
stimulating hormone (TSH), and prolactin. Ames Dwarf mice persistently live
approximately 40%-60% longer than their normal littermates.17
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Previous studies have also compared genetic versus environmental influences in
the progression of sarcopenia. A group of researchers led by Edstrom detected the
importance of metabolism and extent of muscle usage as the mouse aged.18 To determine
the role of metabolism within the aging process, a litter of mice were put on restricted
diets. The results of dietary restriction revealed a reduction in the appearance of several
characteristic features in aging skeletal muscle through the restoration of transcriptional
alterations that naturally occur with the aging process. Activity and exercise
demonstrated similar results. Increasing levels of activity help maintain the current
strength of muscle mass, thus, reversing the detrimental effects of aging on skeletal
muscle.
For this research project, the lower extremity musculature of Ames dwarf mice
was analyzed. The muscle tissues that were removed from the mice were placed on liver
tissue to maintain resting length on a stable surface. The goal was to determine the
number of fast-glycolytic and slow-oxidative muscle fiber cells located within the soleus
(SOL) and extensor digitorum longus (EDL) muscles. Ames dwarf mice have a point
mutation on chromosome 11 and characteristically have primary pituitary hormonal
deficiency caused by reduced anterior pituitary cells. These cells produce and secrete
prolactin, thyroid stimulating hormone (TSH), and growth hormone (GH). It has been
suggested that these hormonal deficiencies play an important role in the longevity of
Ames dwarf mice; in the cases of TSH and GH deficits, the lifespan may be influenced
by lower metabolic rates and reduced premature aging. Furthermore, their small body
size may also impact survival.19,20 Previous research has demonstrated significant
differences in cardiac, liver, and kidney tissues between dwarf mice and normal mice;
12

these differences have been linked to life longevity, enzyme metabolism, and the absence
of anterior pituitary hormones. Because Ames dwarf mice exhibit substantial tissue
variances, current research is now asking, how does muscle tissue vary between wild type
and dwarf mice and does it reveal aerobic-oxidative metabolic shifts or conversion of
type II to type I muscle fibers? Does the delayed aging seen in Ames dwarf mice avoid
the sarcopenic effects in muscle? If it does, how would this discovery contribute to the
research in muscle health in humans? This was the area of focus in this research study. It
aimed to detect differences in muscle fibers as they age. Observations of cross-sectional
muscle area and fiber type composition of age-matched mice (3 month, 6 month and 12
month old) were analyzed and comparisons across ages were obtained.
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CHAPTER III
METHODS
Muscle tissues were obtained from both wild type and Ames dwarf mice. Four
muscles were extracted from bilateral lower extremities including SOL, gastrocnemiusplantaris (GP), EDL, and tibialis anterior (TA). After the muscles were extracted, they
were placed on a slice of liver tissue that was surgically removed from a wild type mouse.
Skeletal Muscle Tissue Acquisition
Tribromoethanol, (2.5% in 0.9% saline per 100 µl/10g body weight) – [~300 µl –
400 µl for wild type mouse], was injected intraperitoneally to anesthetize the animals.
Once the injection was given, the mouse’s pain and corneal reflexes were checked every
couple minutes; when the mouse no longer responded to the stimuli, surgery proceeded.
Low angle cuts were made around the legs and ankles in order to free hind limb
skin. The skin was detached from the muscles by inserting a scissors underneath the skin
and spreading the scissors open to pull the skin away from the surrounding tissues. Cuts
were made up the skin proximally towards the hip and the skin was peeled away. The
distal attachment of the GP and SOL was severed by slicing the tendon at the heel. SOL
was separated from the GP musculature at the knee joint; it was then cut at the knee and
retracted towards the distal end. Another cut was made to remove the SOL. The tissue
was then placed on a piece of liver, covered with Optimal Cutting Temperature (OCT)
compound, and then frozen in isopentane in liquid nitrogen. Next, GP was removed from
14

its attachment at the knee. Following the above procedure, the tissue was then frozen in
isopentane in liquid nitrogen. The third muscle extracted was the TA. Fascia surrounding
TA was removed by toothed forceps; TA was freed by sliding the instrument along the
tibia. The TA tendon was severed at both the ankle and knee. Again, the same freezing
procedure as the GP was utilized. Finally, the EDL was located, removed from its
attachments at the ankle and knee, and frozen in the same manner as the SOL.
Slicing Muscle Tissue
Muscle tissue was sliced using a Cryostat which was cooled to -25˚C (optimal
cutting temperature) for 8 to 10 hours. The cutting blade was rinsed with alcohol,
inserted in to the Cryostat, and allowed to cool for 30 minutes. Tissue samples were
refrigerated at -80˚C; hence, they needed to warm up to -25˚C prior to slicing. Once the
appropriate temperature had been reached, the muscle tissue was set vertically on a metal
plate with OCT to secure the sample. Slicing was done in 50-µm sections (trim) until
arriving at the muscle tissue. The blade was then switched to 10-µm sections (fine). Fifty
10-µm sections were sliced to attain the main portion of the muscle. After reaching the
main muscular portion, 10-µm serial sections were collected and placed on slides. The
slides used for collection were Fisher Superfrost Plus Microscope slides (Fisher Scientific
Pittsburgh, PA. Cat. No. 12-550-15 for 25 x 75 x 1.0 mm). Three sections were placed on
each slide. When thirty sections had been compiled, another fifty 10-µm sections were
skipped. Next, an additional 30 sections of 10-µm was recovered and placed on slides.
This procedure was repeated until the end of the muscle was reached. The slides
containing muscle tissue were then stored in a refrigerator at -20˚C.
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Hematoxylin And Eosin Staining
The slides were submerged in Harris hematoxylin for two minutes and then rinsed
in distilled water twice. Next, the stained slides were transferred to acid alcohol (11 ml
glacial acetic acid, 95 ml ethanol, and 5 ml distilled water) and dipped three times. Again,
they were rinsed in distilled water. The slides were then dipped in ammonium water
(0.588 ml of 28% NH4OH in 250 ml dH2O) six times and rinsed with distilled water. A
working solution of eosin was mixed; it consisted of 100 ml stock eosin, 300 ml 80%
ethanol, and 2.5 ml glacial acetic acid. The slides remained in the working solution for
thirty seconds. Afterwards, the slides were rinsed twice in distilled water. Finally, the
slides were dehydrated, for 15 seconds each, in 75%, 95%, and 100% ethanol and clear
xylene. Once dehydrated, the slides were mounted with Permount and stored at room
temperature.
Immunohistochemistry For Mouse Myosin Heavy Chains
Tissue slides were removed from the freezer and allowed to warm-up to room
temperature. While the slides were warming, a working 1x phosphate buffered saline
(PBS) solution was prepared. The solution was diluted with distilled water and potassium
chloride to achieve a pH of 7.4. This solution was used throughout the procedure for
rinsing the slides in between cellular staining. A total of 18 slides were stained; 8 slides
were stained with fast-twitch, 8 with slow-twitch, and 2 were the control group.
Once the slides achieved room temperature, the tissue samples were encircled
using a PAP pen and then rinsed in 1X PBS for 2 minutes. PAP pens are used for
applying immunohistochemistry to slides; the hydrophobic properties of the pen allow
16

the user to draw barriers on a slide to confine the applied reagents to a defined area. The
encircled area has a visible blue/green marking. For immunohistochemistry, the PAP pen
should be applied following deparaffinization. A series of protein and blocking solutions
were applied to the tissue samples, slides were incubated, and then rinsed in 1X PBS.
First, a mixed solution of 30% hydrogen peroxide and horse serum (30 µl H2O2 + 9 µl
horse serum in 3 ml PBS) was added to the tissues and then incubated for 5 minutes.
Slides were then rinsed in PBS solution twice for 2 minutes. Avidin blocking solution
was allotted for 15 minutes; a 2 minute rinsing in PBS solution followed. Next, biotin
blocking solution was placed on the samples for 15 minutes and then the samples were
rinsed for 2 minutes in PBS. The slides were then incubated and covered for 60 minutes
with a mixture consisting of 36 µl mouse IgG blocking reagent and 1 ml PBS.
Subsequently, the tissues were rinsed in PBS twice for 2 minutes.
Thereafter, mouse on mouse concentrate (M.O.M.), which is a combination of
160 µl of protein concentrate and 2 ml PBS, was placed on the slides and allowed to sit
for 5 minutes. Slides were then stained with either a fast-twitch or slow-twitch protein;
456 µl of M.O.M. diluent + 24 µl of slow antibody protein was added to 8 tissues slides
and 425 µl of M.O.M. diluent + 47 µl of fast antibody protein was placed on another 8
tissue slides. These slides were incubated in 100 µl of primary antibody dilution and
covered for 30 minutes. During the time of incubation, a solution of 1.25 ml of PBS, 1
drop of reagent A and 1 drop of reagent B was prepared and allowed to stand at room
temperature for 30 minutes.
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After the slides were rinsed in PBS solution twice for 2 minutes, they were
incubated in 4 µl of M.O.M. biotinylated anti-mouse IgG reagent and 1 ml M.O.M.
working diluent for 10 minutes. Again, slides were rinsed in PBS for 2 minutes. Next, the
mixture of reagent A & B was applied to the slides for 5 minutes; afterwards, DAB
solution was placed on the slides for 10 minutes. Following the application of DAB, the
slides were rinsed in distilled water for 1 minute and then dehydrated in 70%, 95%, and
100% alcohols and xylene. Slides were mounted with Permount and stored at room
temperature.
Muscle Fiber Counting
Once the slides had been stained, they were observed under a microscope. Tissue
samples were enlarged for proper viewing. Stained muscle fibers were counted, stained
and unstained. The stained fibers were considered to be either fast or slow twitch
depending on the stain used on the tissue sample slides; unstained fibers were considered
to be any muscle fibers that did not take to the specific stain. These fiber counts were
compared between normal and dwarf mice. Please see the results section for further
information.
Determining Cross-Sectional Muscle Area
Cross-sectional areas were measured using the software program, Scion. Ruler
measurements were set at a known length of 1000 micrometers with .981
pixels/micrometers being the measured distance. Stained muscle fiber images were
analyzed using a freehand line drawing tool. Five cells were representative of the entire
tissue sample and were measured twice for increased accuracy in the actual cross18

sectional area of the muscle cell. The average of the 10 areas was used in the final t-test
analysis.
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CHAPTER IV
RESULTS
The following tables demonstrate the differences in muscle fiber counts: fast
twitch versus slow twitch and average muscle fiber composition between wild type and
dwarf mice. Comparisons can be seen across the lifespan in wild type and dwarf mice.
Please see tables 1 through 6 for detailed information and the results section for further
information regarding the laboratory observations.
Wild type Mouse Muscle Fiber Counts
Table 1: Muscle fiber counts for SOL in wild type mice. Fast vs. slow twitch.
Animal #,
Slide Section

Age

Fiber type
stained

Right vs.
Left

# of stained
fibers

# of fast
unstained fibers

Total # of
cells

N4 175

12 mo.

Slow

Right

143
(55.85%)

113
(44.14%)

256
(100%)

N4 176

12 mo.

Fast

Right

92
(42.2%)

126
(57.8%)

218
(100%)

N2 214

3 mo.

Slow

Left

204
(58.45%)

145
(41.54%)

349
(100%)

N2 213

3 mo.

Fast

Left

158
(45.4%)

190
(54.6%)

348
(100%)
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Dwarf Mouse Muscle Fiber Counts
Table 2: Muscle fiber counts for SOL in Ames dwarf mice. Fast vs. slow twitch.
Animal #,
Slide
Section

Age

Fiber type
stained

Right vs.
left

# of stained
fibers

# of
unstained
fibers

Total #
of cells

D1 10x

6 mo.

Fast

Right

104
(30.3%)

239
(69.7%)

343
(100%)

D1 10x

6 mo.

Slow

Right

235
(63.5%)

135
(36.5%)

370
(100%)

D2 10x

6 mo.

Fast

Right

194
(35.5%)

352
(64.5%)

546
(100%)

D2 10x

6 mo.

Slow

Right

387
(68.5%)

178
(31.5%)

565
(100%)

Comparisons between table 1 and 2 reveal composition differences in wild type
and dwarf mice. As expected, the dwarf musculature has a higher percentage of slow
twitch fibers. Although it is not a huge difference, the percentages do correlate with the
normal percentage expected in both wild type and dwarf mice. The percentage of slow
twitch fibers in SOL was 60-70% in dwarf compared to wild type of 50-60%.
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Cross-sectional areas of soleus muscles in wild-type mice and Ames dwarf mice.
Table 3: Cross-sectional areas for 12 month old, wild type mouse N4. Five different cells,
representative of the entire tissue sample were measured twice for increased accuracy in
actual area for muscle cells. Measurements are in micrometers.
Sample 12 H&E R SOL N4
Cell #

Area

1

2246

2

2181

3

3484

4

3415

5

1695

6

1621

7

1357

8

1347

9

3386

10

3307

Average Cross-sectional
Muscle Area

2403.9

Table 4: Cross sectional area for 3 month old, wild-type mouse N2. Measurements are in
micrometers. The bolded numbers are essential in the analysis for determining the crosssectional area of muscle fiber cells.
Sample 3 H&E L SOL N2
Cell #

Area

1

2471.01

2

2665.32

3

2087.57

4

2238.25

5

3387.5

6

3598.44

7

2339.04

8

2344.23

9

2519.84

10

2744.29
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Average Cross-Sectional
Muscle Area

2639.55

Table 5: Cross sectional area for 6 month old, dwarf mouse, D1. Measurements are in
micrometers. The bolded numbers are essential in the analysis of the cross-sectional area
of the muscle fiber cells.
Sample D1 SOL 10x H&E
Cell #

Area

1

808.43

2

778.29

3

484.23

4

457.21

5

659.84

6

653.6

7

871.81

8

841.68

9

814.66

10

788.69

Average Cross-Sectional
Muscle Area

715.84

Comparing tables 3 and 4 show the mean cross-sectional area differences between
the 3 month old and 12 month old wild type mice were not significant (P=.478). The
average muscle area for the wild type 3 month old was 2639.55; the average muscle area
for the 12 month old was 2403.9. However, differences were significant between dwarf
and wild type cross-sectional areas (P<.001) with the dwarf mean area being about 25%
the size of the wild type. The dwarf average muscle area was 715.84. This result was
expected considering the smaller nature of the dwarf mouse.
Comparisons were drawn between the 3 month and 12 month normal mice and
the 3 month normal mouse and the 3 month dwarf mouse. Using a two-tailed t-test
analysis, the statistics for comparing the normal mice had a p value = 0.478, standard
deviation of 905.05 for the 12 month old, standard deviation of 491.7 for the 3 month old,
standard error of 286.2 for the 12 month old, and standard error of 155.5 for the 3 month
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old. The preceding analysis may demonstrate the differences seen as a wild type mouse
ages. The percentage of muscle fibers, specifically fast twitch fibers decreases;
additionally, cross-sectional muscle areas in the SOL decrease as well. These results
would be expected in a typical aging process of a wild type mouse.
Comparisons between the 3 month old wild type mouse and 3 month old dwarf
mouse were calculated using a two-tailed t-test analysis. Statistics demonstrated a p value
of less than 0.0001. Standard deviation of 147.3 and standard error of 46.58 for the dwarf
mouse and standard deviation of 491.7 and standard error of 155.5 for the wild type
mouse was calculated.
Conclusions that can be drawn from the comparison between the wild type and
dwarf mice include a smaller cross-sectional muscle area in a dwarf mouse and no drastic
change in the percentages of fast and slow twitch muscle fibers as the dwarf mouse ages.
This is considered normal for a dwarf mouse; the percentage of fast twitch and slow
twitch muscle fibers remain relatively constant as the mouse ages. Cross sectional muscle
area was expected to be smaller in the dwarf mice considering their smaller size in
comparison to the normal mice. Furthermore, it was also expected for there to be
differences in fiber length and cross-sectional muscle area between wild type and dwarf
mice.

24

CHAPTER V
DISCUSSION
This study analyzed the counts of fast-twitch and slow-twitch muscle fibers and
cross-sectional muscle fiber areas of tissue samples. It allowed the student researchers to
perform microscopic surgery to remove the lower extremity musculature, obtain muscle
tissue samples utilizing a Cryostat, prepare and stain tissue samples, and learn how to
operate software programs to analyze results and draw comparisons. This study also
demonstrated some main differences in muscle size and fiber composition between wild
type and Ames dwarf mice. It revealed typically observed percentages of fast and slow
twitch muscle fibers and muscle areas for the two mice samples. The wild type mice were
expected to have a change in muscle fiber composition as they aged; additionally, an
overall larger surface area in the lower extremity musculature was expected due to the
bigger size of this mouse. In contrast, the dwarf mice did not demonstrate a significant
change in muscle fiber composition as they aged and their muscle surface area was much
smaller compared to the wild type mice.
Some limitations of the study include small sample size and younger age of the
mice. All mice were between 3 months-12 months of age. Much of the specific aging
processes could not be well observed in this study secondary to the age of the mice
involved. Thus, conclusions on the aging process and sarcopenic effects in mouse
musculature cannot be formulated. Furthermore, only one dwarf mouse soleus muscle’s
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fiber composition was able to be analyzed due to the limited access of the software
program and time constraints.
Future studies should incorporate bigger sample sizes and newer software
programs for analysis to determine actual muscle fiber composition changes and what
those changes might indicate. Studies should also be performed on human subjects
willing to undergo dietary restrictions and exercise protocol to determine if muscle fiber
composition changes, or lack thereof, can be observed.
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